Lumateperone
An atypical antipsychotic used to treat schizophrenia and depressive episodes associated with bipolar disorder. It has a unique pharmacological profile acting simultaneously on dopamine, serotonin, and glutamate receptors.
分子量
393.5000 g/mol
LogP
3.80
TPSA
26.80 Ų
リピンスキーの五則
適合
治療領域
作用機序
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …
2D構造
Cite this structure
Embed this structure
SMILES
CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12
InChI
InChI=1S/C24H28FN3O/c1-26-14-15-28-21-11-13-27(16-20(21)19-4-2-5-22(26)24(19)28)12-3-6-23(29)17-7-9-18(25)10-8-17/h2,4-5,7-10,20-21H,3,6,11-16H2,1H3/t20-,21-/m0/s1
Molecular Formula
C24H28FN3O
HBD / HBA
- / 5
回転可能結合数
5
重原子数
29
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
An atypical antipsychotic used to treat schizophrenia and depressive episodes associated with bipolar disorder. It has a unique pharmacological profile acting simultaneously on dopamine, serotonin, and glutamate receptors.
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.
Yes, Lumateperone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3306803. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 21302490. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="lumateperone"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/lumateperone/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/lumateperone/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/lumateperone/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="lumateperone"></drugfyi-drug>